Novogen Ltd, the registered owner of the European Patent "Use of isoflavone phyto-oestrogen extracts of soy or clover (EPO 656786 B1) has reached an agreement with Laboratorios Casen-Fleet for a licence in Spain to the Novogen Patent.
Laboratorios Casen-Fleet the Spanish affiliate of the US multinational healthcare company Fleet Laboratories has recently acquired the red clover isoflavone based menopause product Fitogyn from Laboratorios Gynea S.A. In conjunction with the product acquisition Laboratorios Casen Fleet and Novogen have agreed on confidential terms for a Patent Licence Agreement.
The chief executive of Novogen, Christopher Naughton, said Novogen was dedicated to the development of isoflavonoid technology, protected by intellectual property, in both the dietary supplement and prescription pharmaceutical arenas. In Europe Novogen has negotiated Patent Licence Agreements with Laboratorios Casen-Fleet and Melbrosin International (manufacturer of Menoflavon).
Novogen's patented dietary supplement products are Promensil, for women's health including the relief of menopausal symptoms, and Trinovin, for prostate health. These brands are marketed directly by Novogen in Australia, Canada and UK, and under licence to distributors in the USA, Europe, South East Asia and South Africa.
Naughton added that, "Since 2005 Novogen has successfully enforced its isoflavone patent portfolio against USA companies such as GNC, NBTY Inc., Natural Alternatives International Inc, Swanson Health Products and Chattem Inc and Canadian companies such as Swiss Herbal, Sante Naturelle and Genuine Health".
Novogen Ltd is an Australian biotechnology company that has patented isoflavone technology for the treatment and prevention of degenerative diseases and disorders. Over the past ten years, Novogen has conducted the largest and most comprehensive isoflavone clinical testing programmes in the world. Novogen is involved in drug discovery and product development for disorders that are commonly associated with aging and coordinates an international clinical research and development program with external collaborators, hospitals and universities.